Federated Hermes’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.6M | Sell |
1,590,331
-195,690
| -11% | -$3.7M | 0.04% | 392 |
|
|
2026
Q1 | $38.9M | Buy |
1,786,021
+472,708
| +36% | +$9.15M | 0.06% | 319 |
|
|
2025
Q4 | $28.3M | Buy |
1,313,313
+4,622
| +0.4% | +$97.4K | 0.05% | 373 |
|
|
2025
Q3 | $25.2M | Buy |
1,308,691
+492
| +0% | +$8.77K | 0.04% | 390 |
|
|
2025
Q2 | $22.4M | Buy |
1,308,199
+1,016,069
| +348% | +$43.3M | 0.04% | 400 |
|
|
2025
Q1 | $18.6M | Sell |
292,130
-88,288
| -23% | -$9.29M | 0.04% | 416 |
|
|
2024
Q4 | $46.3M | Sell |
380,418
-128,418
| -25% | -$15.7M | 0.1% | 248 |
|
|
2024
Q3 | $63.5M | Buy |
508,836
+507
| +0.1% | +$70.1K | 0.14% | 191 |
|
|
2024
Q2 | $80.3M | Sell |
508,329
-101,887
| -17% | -$13.1M | 0.19% | 132 |
|
|
2024
Q1 | $79M | Sell |
610,216
-98,174
| -14% | -$12M | 0.18% | 149 |
|
|
2023
Q4 | $68.3M | Sell |
708,390
-254,659
| -26% | -$24.4M | 0.17% | 157 |
|
|
2023
Q3 | $117M | Sell |
963,049
-1,898
| -0.2% | -$215K | 0.31% | 70 |
|
|
2023
Q2 | $111M | Buy |
964,947
+148,025
| +18% | +$19.1M | 0.27% | 77 |
|
|
2023
Q1 | $113M | Buy |
816,922
+37,479
| +5% | +$4.86M | 0.28% | 76 |
|
|
2022
Q4 | $101M | Buy |
779,443
+4,569
| +0.6% | +$529K | 0.28% | 68 |
|
|
2022
Q3 | $85.7M | Buy |
774,874
+70,774
| +10% | +$7.13M | 0.25% | 89 |
|
|
2022
Q2 | $52.8M | Buy |
704,100
+517
| +0.1% | +$38K | 0.14% | 192 |
|
|
2022
Q1 | $55M | Buy |
703,583
+24,609
| +4% | +$1.88M | 0.12% | 213 |
|
|
2021
Q4 | $61.1M | Buy |
678,974
+350,033
| +106% | +$29.9M | 0.11% | 234 |
|
|
2021
Q3 | $30.4M | Buy |
328,941
+102,858
| +45% | +$7.92M | 0.06% | 384 |
|
|
2021
Q2 | $17.6M | Sell |
226,083
-55,452
| -20% | -$4.2M | 0.03% | 511 |
|
|
2021
Q1 | $21M | Sell |
281,535
-2,391
| -0.8% | -$221K | 0.04% | 483 |
|
|
2020
Q4 | $48.4M | Sell |
283,926
-24,867
| -8% | -$3.68M | 0.1% | 257 |
|
|
2020
Q3 | $43.4M | Buy |
308,793
+85,003
| +38% | +$12.9M | 0.1% | 232 |
|
|
2020
Q2 | $35.9M | Buy |
223,790
+25,086
| +13% | +$3.41M | 0.09% | 266 |
|
|
2020
Q1 | $19.4M | Buy |
198,704
+97,326
| +96% | +$11.1M | 0.06% | 339 |
|
|
2019
Q4 | $13.1M | Buy |
+101,378
| New | +$10.2M | 0.03% | 536 |
|
|
2019
Q1 | – | Sell |
-26
| Closed | -$3K | – | 2226 |
|
|
2018
Q4 | $3K | Sell |
26
-9,415
| -100% | -$1.18M | ﹤0.01% | 2052 |
|
|
2018
Q3 | $1.52M | Sell |
9,441
-10,270
| -52% | -$1.4M | ﹤0.01% | 1208 |
|
|
2018
Q2 | $2.6M | Sell |
19,711
-33,658
| -63% | -$3.17M | 0.01% | 906 |
|
|
2018
Q1 | $3.95M | Buy |
53,369
+4,460
| +9% | +$297K | 0.01% | 703 |
|
|
2017
Q4 | $2.72M | Buy |
+48,909
| New | +$2.59M | 0.01% | 819 |
|
|
2016
Q4 | – | Sell |
-3,887
| Closed | -$239K | – | 2165 |
|
|
2016
Q3 | $239K | Buy |
+3,887
| New | +$118K | ﹤0.01% | 1448 |
|
|
2013
Q4 | – | Sell |
-30,000
| Closed | -$1.42M | – | 1794 |
|
|
2013
Q3 | $1.42M | Buy |
+30,000
| New | +$1.16M | 0.01% | 1029 |
|
Other funds holding SRPT
EAM
Federated Hermes's SRPT Position: Q2 2026 in Review
Federated Hermes reduced its Sarepta Therapeutics (SRPT) stake by 11% in Q2 2026, selling an estimated $3.7M and leaving 1,590,331 shares worth $28.6M. The position accounts for 0.04% of the portfolio, ranked #392.
Federated Hermes first reported a position in SRPT in Q3 2013 and has held it in 34 quarters since. The position peaked at $117M in Q3 2023. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Federated Hermes held 1,590,331 shares of Sarepta Therapeutics worth $28.6M as of Q2 2026.
- Federated Hermes sold 195,690 Sarepta Therapeutics shares in Q2 2026, an estimated $3.7M.
- Sarepta Therapeutics made up 0.04% of Federated Hermes's portfolio in Q2 2026, its #392 holding.
- Federated Hermes first reported a position in Sarepta Therapeutics in Q3 2013 and has held it in 34 quarters since.
- Federated Hermes's Sarepta Therapeutics position peaked at $117M in Q3 2023.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.